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Abstract
Rationale Suvorexant is a first-in-class orexin receptor antag-
onist for treating insomnia. There is a general concern that
hypnotics may impair next-morning driving ability.
Objective The objective of this study was to evaluate next-
morning driving performance in older adults after single and
repeated doses of suvorexant.
Methods Double-blind, randomized, placebo-controlled, 4-
period crossover study in 24 healthy volunteers (10 females),
aged 65–80 years. Subjects were treated with suvorexant (15
and 30 mg) for eight consecutive nights, zopiclone 7.5 mg
nightly on days 1 and 8, and placebo. Driving performance
was assessed on days 2 and 9 (9 h after dosing) using a 1-h
standardized highway driving test in normal traffic, measuring
standard deviation of lateral position (SDLP). Drug-placebo
differences in SDLP >2.4 cm were considered to reflect clin-
ically meaningful driving impairment.
Results Driving performance as measured by SDLP was not
impaired following suvorexant. Mean drug–placebo differ-
ences in SDLP following suvorexant 15 and 30 mg on day 2
and 9 were 0.6 cm or less. Their 90 % CIs were all below the
threshold of 2.4 cm for clinical relevance and included zero,
indicating effects were not clinically meaningful or statistical-
ly significant. Symmetry analysis showed no significant dif-
ferences between the number of participants who had SDLP
differences >2.4 cm and those who had SDLP differences <
−2.4 cm following suvorexant.
Conclusions There was no clinically meaningful residual ef-
fect of suvorexant 15 and 30 mg on next-morning driving (9 h
after bedtime dosing) in healthy older adults, as assessed by
mean changes in SDLP and by the number of participants on
drug versus placebo that exceeded a predetermined threshold
for clinically meaningful impairment.
Keywords Hypnotics . Suvorexant . Zopiclone . Orexin
antagonist . Driving . Elderly
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Introduction
Suvorexant (MK-4305, Belsomra®) is a hypnotic drug with a
novel mechanism of action, that is approved in the USA since
2014 for the treatment of adults with insomnia, who have
difficulty falling asleep and/or staying asleep (Merck & Co.,
Inc. 2014). Suvorexant acts as a selective antagonist at orexin-
1 and orexin-2 receptors (Cox et al. 2010). Orexin (or
hypocretin) is produced by neurons in the lateral hypothala-
mus and plays a major role in the regulation of sleep and wake
state via projections to orexin receptors in wake-active mono-
aminergic and cholinergic systems (De Lecea and Huerta
2014; Fulcher et al. 2014). Orexin neurons are most active
during wakefulness and fall silent during sleep thereby con-
tributing to the maintenance of wakefulness. Loss of orexin
neurons results in narcolepsy, a condition characterized by
excessive daytime sleepiness and uncontrolled sleep/wake
transitions, and may be accompanied by cataplexy (a sudden
loss of muscle tone).
Suvorexant is well absorbed following oral administration,
reaching maximum concentrations in plasma between 1.5 and
4 h after intake (Sun et al. 2013). Plasma concentration de-
creases thereafter with a half-life of about 12 h, and steady
state is reached after 3 days of dosing. Clinical studies have
shown that suvorexant in doses of 10mg or more significantly
improves subjective and objective measures of sleep in
healthy volunteers and insomnia patients (Sun et al. 2013;
Herring et al. 2012, 2016; Michelson et al. 2014). Phase-3
trials included both elderly and non-elderly adults with insom-
nia (Michelson et al. 2014; Herring et al. 2016). A 1-year
multicenter phase-3 trial showed that suvorexant 40 and
30 mg had sustained effects on subjective total sleep time up
to 1 year (Michelson et al. 2014). Furthermore, suvorexant
was well tolerated and did not show rebound or withdrawal
effects upon discontinuation. The most common adverse
events associated with suvorexant are primarily extensions
of the drug’s pharmacological activity, i.e., somnolence, fa-
tigue, and dry mouth (Michelson et al. 2014). The recom-
mended dose in the USA for both elderly and non-elderly
adults with insomnia is 10 mg, which may be increased to a
maximum of 20 mg.
A general concern associated with the use of hypnotics
is their potential to impair driving ability the morning
after use, due to residual sedative effects (Food and
Drug Administration 2015; Dassanayake et al. 2011;
Smink et al. 2010; Vermeeren 2004). Results from initial
screening of suvorexant’s potential to impair next-day
performance using psychomotor tests (e.g., simple reac-
tion time tests and digit symbol substitution tests) sug-
gested that residual effects of suvorexant are minor after
bedtime doses up to 40 mg (Sun et al. 2013; Herring et al.
2012). Subsequently, a dedicated driving study in a group
of 28 healthy non-elderly adults (age range 21–64 years)
was conducted to evaluate effects of single and repeated
doses of suvorexant 20 and 40 mg on next-morning per-
formance in an on-the-road driving test (Vermeeren et al.
2015). Results showed that measurable impairment oc-
curred after suvorexant as compared to placebo, but the
mean effects on SDLP were less severe than previously
found for alcohol in blood concentrations of 0.5 g/L
(Louwerens et al. 1987), which is the legal limit for driv-
ing in most countries. The effects were therefore not con-
sidered to be clinically meaningful. Nonetheless, four sub-
jects requested that a total of five driving tests be stopped
before scheduled completion, because they felt too
drowsy to continue safely. In addition, analysis of indi-
vidual changes in driving performance showed that a sta-
tistically significant larger number of subjects showed im-
pairment as compared to improvement after single doses
of 20 and 40 mg, and after repeated doses of 40 mg.
Notably, correlations between changes in driving perfor-
mance and plasma concentrations of suvorexant were very
low (<0.3). It was concluded that the residual effects of
suvorexant 20 and 40 mg are on average not clinically
meaningful, but there may be some individuals who ex-
perience next-day effects (Vermeeren et al. 2015).
A question that remains is whether suvorexant has clinical-
ly meaningful residual effects on driving in older adults (i.e.,
>65 years). The highest prevalence of sleeping problems is
found in older people, and most users of hypnotics are elderly
(Drake et al. 2003; Glass et al. 2005; Bain 2006). Drug effects
may be more pronounced in elderly drivers because of age-
related reductions in liver capacity and lean body mass. In
addition, the sensitivity of the hypnotic effects may be in-
creased (Woodward 1999). The aim of the present study was
therefore to evaluate next-morning driving performance in
adults aged 65 to 80 years, after single and repeated doses of
suvorexant 15 and 30 mg. The doses studied were those eval-
uated in phase-3 trials in elderly patients (Michelson et al.
2014; Herring et al. 2016). Zopiclone 7.5 mg was selected
as an active control to demonstrate assay sensitivity versus
placebo, as has been the case in other studies (Leufkens and
Vermeeren 2014; Mets et al. 2011; Ramaekers et al. 2011;
Vermeeren et al. 2014, 2015).
3342 Psychopharmacology (2016) 233:3341–3351
Methods
Participants
Twenty-four participants (14 males and 10 females) were re-
cruited from a database. Healthy volunteers between 65 and
80 years of age (inclusive) were eligible to enroll if they pos-
sessed a valid driver’s license, had driving experience of
≥3000 km/year on average within the last 3 years, body mass
index between 18 and 30 kg/m2 (inclusive), normal vision
(corrected or uncorrected), and a regular sleep pattern (bed-
time between 21:00 and 24:00). Participants were required to
be in good health, as confirmed by their medical history, phys-
ical examination, vital sign measurement, electrocardiogram,
and laboratory safety tests (blood chemistry and hematology).
Participants who met any of the following criteria were ex-
cluded from the study: history or present evidence of any clin-
ically significant physical, neurological, psychiatric, or sleep
disorders, alcoholism or drug abuse; use of medication known
to affect driving performance or hepatic drug metabolism; esti-
mated creatinine clearance ≤60 mL/min based on the Cockroft-
Gault equation; major surgery, blood donation or participation in
any other clinical trial within 4 weeks prior to screening;
smoking >6 cigarettes per week; alcohol consumption >3 drinks
per day; caffeine consumption >6 servings per day (1 serving
each equivalent to 120mg caffeine). All participants were tested
for drug use (amphetamines, benzodiazepines, barbiturates, can-
nabis, cocaine, methadone, tricyclic antidepressant, and opiates),
at pre-study screening and at the start of each test session.
During participation subjects were required to abstain from
prescription and non-prescription medication, and grapefruits
or grapefruit products. They also had to refrain from smoking
and/or consuming caffeine and alcohol from the time of arrival
at the site on treatment days until the completion of all tests the
next day. In addition, alcoholic drinks, fruit juice, caffeine, and
food were not permitted from 48, 12, 10, and 4 h prior to
arrival, respectively. Dietary restrictions were to avoid effects
which could influence driving (alcohol, caffeine, and nicotine)
and/or affect the results of pharmacokinetic testing (juice and
food). Furthermore, participants were required not to drive
their own vehicles from intake of the first dose until 24 h after
the last dose of each treatment period.
Ethical approval was obtained from the Medical Ethics
Committee of ZNA Middelheim, Antwerp, Belgium, and all
volunteers provided written informed consent prior to enroll-
ment. The study was carried out in compliancewith guidelines
for Good Clinical Practice.
Design
The study (Merck protocol 039) was conducted from
February to June 2011, according to a randomized, double-
blind, placebo and active drug controlled, 4-period crossover
design. A four by four Latin Square design balanced for first-
order carryover was used. Subjects were randomized to one of
four treatment sequences, using validated randomization soft-
ware. Each treatment period lasted for 8 days, and residual
effects were assessed in the mornings of day 2 and 9.
Treatments were suvorexant 15 mg, suvorexant 30 mg and
placebo on days 1 to 8, and zopiclone 7.5 mg on day 1 and 8
only, with placebo given for the 6 days in between (day 2 to 7).
Order of treatment conditions was balanced over subjects.
Washout between treatments periods was at least 7 days.
Single-dose zopiclone was included as an active control to dem-
onstrate assay sensitivity versus placebo on day 2 and day 9.
Assessments
Highway driving test
Residual effects were assessed using a standardized on-the-
road driving test, which measures road tracking performance
(O’Hanlon 1984). In this test, subjects operated a specially
instrumented vehicle for about 1 h over a 100-km (61-mile)
primary highway circuit (road E313) between the Belgian cities
of Tongres andDiepenbeek, accompanied by a licensed driving
instructor having access to dual controls (brakes and accelera-
tor). The subjects’ task is to drive with a steady lateral position
between the delineated boundaries of the slower (right) traffic
lane, while maintaining a constant speed of 95 km/h (58 mph).
Subjects may deviate from those instructions only to pass a
slower vehicle and to leave and re-enter the highway at the
turnaround points. During the drive, the vehicle’s speed and
lateral distance to the left lane-line are continuously recorded.
These signals are digitized at a rate of 4 Hz and stored on an
onboard computer disk file for later preprocessing and analysis.
The primary outcome variable is standard deviation of lateral
position (SDLP in cm), which is a measure of “weaving” or
road tracking error. The secondary outcome variable is standard
deviation of speed (SDS in km/h), which is a measure of speed
control. Performance in this test has repeatedly been found
sensitive to residual effects of hypnotics, including zopiclone
7.5 mg (Vermeeren et al. 2015; Leufkens and Vermeeren 2009,
2014; Leufkens et al. 2014; Vermeeren et al. 2014).
Word learning test
The Word Learning Test is a verbal memory test for the as-
sessment of immediate and delayed free recall and delayed
recognition. In this test, a sequence of 15 monosyllabic nouns
is shown on a computer display at a rate of 1 per 2 s.
Immediately thereafter the subject is required to verbally recall
as many words as possible. The sequence is repeated on four
more trials, and the sum of separate trial scores is the
Immediate Recall Score. After a delay of 30 min, the subject
is again required to recall as many words as possible without
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prompting. The total number of words correctly recalled is the
Delayed Recall Score. Finally, the subject is shown a sequence
of 30words on the computer display, including 15 words from
the original set and 15 new words in random order. The sub-
ject has to indicate as quickly as possible whether a word
originates from the original set or not by pressing correspond-
ing buttons. The number and speed of correct responses are
recorded as the Recognition Score and the Recognition
Reaction Time (in ms), respectively. Nine parallel lists were
used, with a different list for each of the 8 testing days and the
training. Lists were balanced across treatments. Performance
in this test has repeatedly been found sensitive to residual ef-
fects of zopiclone 7.5 mg (Vermeeren et al. 1998a, 2002, 2015;
Leufkens and Vermeeren 2009; Leufkens et al. 2009, 2014).
Body sway
The ability of subjects to maintain a balanced body posture was
evaluated by measures of body sway during quiet stance main-
tenance using a portable AccuSwayPlus force platform
(Advanced Mechanical Technology Inc., Watertown, MA). In
this test, subjects are instructed to stand as still as possible on the
platform in an upright position with bare feet placed parallel at
hip width, arms relaxed along the body and facing forward. The
system measures ground reacting force and movement in three
orthogonal directions, providing the center of foot pressure
(CoP) coordinates. These data are used to calculate the extent
of movement of the CoP during each recording. Dependent
variables are the path length of the CoP (in cm) and the surface
area of 95% confidence ellipse enclosing the CoP (A95 in cm2).
A95 is the primary measure, as it has shown to be a more
sensitive measure of postural stability (Boyle et al. 2009;
Norris et al. 2005; Otmani et al. 2012). Each test consisted of
six 40-s trial recordings comprising two task conditions. In the
first three trials, subjects were instructed to keep their eyes open
and fixated on a point 50 cm in front of them at eye level. In the
following three trials, subjects were instructed to keep their eyes
closed. A95 and CoP scores were averaged over each set of
three trials. Foot position is standardized between trials bymark-
ings on the platform. Recent studies have shown that postural
balance as measured with this test is sensitive to low and mod-
erate doses of alcohol, sleep deprivation, and residual effects of
hypnotics (Vermeeren et al. 2015; Jongen et al. 2014, 2015).
Digit symbol substitution test
The Digit Symbol Substitution Test (DSST) measures process-
ing speed and working memory. It is a computerized version
(Ramaekers et al. 1999) of the original paper and pencil test
taken from the Wechsler Adults Intelligence Scale. The subject
is shown an encoding scheme consisting of a row of squares at
the top of a touch-screen, wherein nine digits are randomly
associated with particular symbols. The same symbols are
presented in a fixed sequence at the bottom of the screen as a
row of separate response buttons. The encoding scheme and the
response buttons remain visible while the subject is shown suc-
cessive presentations of a single digit at the center of the screen.
The subject is required to match each digit with a symbol from
the encoding list as rapidly as possible by touching the corre-
sponding symbol on the touch-screen. The number of digits
correctly encoded within 3 min is the performance measure.
Performance in this test has previously been found sensitive to
residual effects of zopiclone 7.5 mg (Vermeeren et al. 2015;
Leufkens et al. 2009; Mets et al. 2011).
Subjective ratings
Before starting the cognitive tests, subjects indicated their
subjective feelings using the Bond and Lader’s 16-item mood
scale for providing three factor analytically defined summary
scores: “alertness,” “contentedness,” and “calmness” (Bond
and Lader 1974). The scale for alertness summary scores
ranges from 0 to 27, where zero corresponds to most alert.
The driving instructors used two visual-analog scales for de-
scribing the subject’s driving quality and apparent sedation at
the conclusion of the driving test, where zero corresponds to
best driving quality and lowest sedation.
Pharmacokinetics
Blood samples (7 mL) for suvorexant and zopiclone determina-
tions were collected after driving, at approximately 11 h post
dose. Plasma samples were stored and frozen at −20 °C and later
analyzed. The analytical methods for the determination of
suvorexant were based on a liquid–liquid extraction of drug
from human plasma. The drug and internal standard were sepa-
rated using reverse-phase high-performance liquid chromatog-
raphy (HPLC) and detected with tandem mass spectrometry
(LC-MS/MS), employing a heated nebulizer (HN) interface in
the positive ion mode and multiple reaction monitoring (MRM)
mode. The lower limit of quantification (LLOQ) for this method
was 1 ng/mL with a linear calibration range from 1 to 1000 ng/
mL. Samples were assayed by WuXi AppTec Co. (Shanghai,
China). The analytical methods for the determination of
zopiclone were based on a liquid–liquid extraction of drug from
human plasma. The drug and internal standard were separated
using reverse-phase HPLC and detected with LC-MS/MS. The
LLOQ for this method was 0.30 ng/mL with a linear calibration
range from 0.30 to 150 ng/mL. Samples were assayed by
PharmaNet Canada (Québec, Canada).
Procedure
Within 2 weeks before the first treatment period, subjects slept
one night in the same facilities as during treatment conditions,
to overcome possible sleep disturbances associated with
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sleeping in an unfamiliar environment. In the evening preced-
ing their habituation night and the following morning, subjects
were individually trained to perform all tests, including the
driving test.
On day 1 of each treatment period, subjects arrived at the
Clinical Pharmacology Unit in Antwerp at approximately
17:00, upon which their eligibility and compliance with study
restrictions were verified by questioning, urine screens for
drugs of abuse and pregnancy, breath testing for alcohol, and
measurement of vital signs. If all the previous requirements
were fulfilled, subjects were provided with a standard dinner
at 18:30 and then transferred, under surveillance to a hotel in
the Belgian city Tongres, nearby the driving area.
Amaximum of four subjects were treated on the same night
and tested the following day with 5-min difference between
their activities. Subjects were fasted for at least 4 h prior to
dosing. At 23:15, the first subject was administered drug or
placebo with 240 mL water in the presence of an investigator
and retired to bed. At 07:15 on day 2, the first subject was
awakened and vital signs were measured. Following toilet and
dress, subjects were provided a standardized light breakfast
without caffeine and transported to the highway. The first
driving test started at approximately 08:15, i.e., 9 h after bed-
time dosing. After completion of the driving test, subjects
were transported to the hotel for further assessments.
Approximately 11 h after dosing, a blood sample was taken
and vital signs were measured. Subsequently, subjects per-
formed the immediate recall part of the Word Learning test,
the DSST, the balance test, and the delayed recall and recog-
nition parts of the Word Learning test, in fixed order. Upon
completion of all tests at approximately 11:15, subjects were
served a light snack and transported back to the Clinical
Pharmacology Unit in Antwerp where they remained under
supervision for days 2 to 7 of all treatment periods. On day 8,
subjects were again transferred to a hotel in the Belgian city
Tongres, nearby the driving area, after which the same proce-
dures as outlined above for days 1 and 2 were followed.
Approximately 14 days after the last treatment period, sub-
jects’ health and well-being were confirmed by questioning
them about adverse events and by physical examination and
laboratory tests (blood chemistry and hematology).
Statistical analyses
The primary endpoint was mean SDLP. Secondary endpoints
were symmetry analysis of individual changes from placebo
in SDLP (see below) and mean word learning and body sway
test scores. Mean DSST and subjective rating scores were
exploratory endpoints. Sample size was determined based on
power calculations to rule out a clinically relevant mean dif-
ference in SDLP between suvorexant and placebo, defined as
the 90 % confidence interval (CI) for the mean difference in
SDLP falling below 2.4 cm (equivalent to a one-sided 95 %
upper confidence interval for the difference). A mean increase
in SDLP of 2.4 cm as compared to placebo corresponds to the
effects previously found for alcohol while subjects drove with
average blood alcohol concentrations of 0.5 g/L (Louwerens
et al. 1987). Assuming a within-subject variance in SDLP of
3.55 cm2 based on a previous study (Ramaekers et al. 2011),
and a sample size of 24, the study would have a probability of
at least 0.80 that the 90 % CI would fall below 2.4 cm if the
true mean difference was as high as 1.0 cm.
All performance parameters were analyzed using a linear
mixed effects model for repeated measures with fixed factors
for Treatment (suvorexant 15 and 30 mg, zopiclone, and pla-
cebo, abbreviated as S15, S30, ZOP, and PBO, respectively),
Day (D2 and D9), Period (1 to 4), and a Treatment by Day
interaction and a random factor for Subject.
As a secondary analysis, SDLP was also analyzed using
symmetry analysis of individual changes from placebo in
SDLP. To perform this symmetry analysis, generalized sign
tests were used for each treatment condition and treatment day
separately to test whether the number of subjects with an in-
crease in SDLP ≥2.4 cm (reflecting impairment) differed sig-
nificantly from the number of subjects with a decrease in
SDLP of −2.4 cm or more (reflecting improvement).
All statistical analyses were done by using the SAS statis-
tical program version 9.3 (SAS Institute Inc. Cary, NC). No
adjustments were made for multiple comparisons.
Results
Demographic data
All 24 enrolled participants completed the study. Their mean ±
standard deviation (SD) age was 68.8 ± 2.7 years (range 65 to
76 years). Their mean ± SD body mass index was
25.8 ± 2.1 kg/m2. Mean ± SD body weight was
79.3 ± 7.2 kg for the males and 63.5 ± 9.7 kg for the females.
All participants were Caucasian.
Driving
One driving test, of a 72-year-old female subject, was terminated
prematurely by the driving instructor, because he judged the
subject too drowsy to continue safely. The test was stopped after
45 min on D2 of PBO. SDLP score for this test was 22.2 cm as
calculated from the data collected until the termination of the
ride. None of the tests were stopped in S15, S30, and ZOP.
As shown in Table 1, mean changes from placebo in SDLP
scores in S15 and S30 were very small on both test days: they
ranged from −0.43 (on D2 of S15) to +0.60 (on D9 of S30).
None of these changes were statistically significant, or clini-
cally meaningful, as determined by the lower limits of the
90 % CI of these changes which all fell below 0 cm, and the
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upper limits of the 90%CIwhich all fell below the criterion of
2.4 cm, respectively.
In ZOP, mean SDLP was increased by 1.89 cm (90 % CI
1.22 to 2.55) on D2 and by 1.17 cm (90 % CI 0.51 to 1.84) on
D9. These results show that effects of zopiclone on driving
were statistically significant on both days (demonstrating as-
say sensitivity) and clinically relevant on D2, but not on D9.
Individual changes from placebo in SDLP are shown in
Fig. 1.
Symmetry analysis showed that significantly more subjects
showed an increase in SDLP ≥2.4 cm than a decrease in SDLP
of the same magnitude on both treatment days in ZOP, but not
in S15 and S30 (Table 2).
In line with results of SDLP, variability in speed (SD
Speed) was significantly increased compared to placebo on
D2 and D9 in ZOP, but not in S15 and S30 (Table 1).
Word learning
No statistically significant impairment was observed in imme-
diate and delayed recall of words and in speed of recognition
in the Word Learning Test (Table 1). Only the total number of
Table 1 Model-based mean performance scores and mean drug-placebo changes (90 % CI) at both test days in each treatment condition, n = 24
Means Treatment differences vs PBO, mean (90 % CI)
Day PBO S15 S30 ZOP S15 S30 ZOP
Driving test
SDLP (cm) 2 16.67 16.24 17.04 18.56 −0.43 (−1.10,0.23) 0.37 (−0.30,1.03) 1.89 (1.22,2.55)
9 15.41 15.50 16.01 16.58 0.09 (−0.58,0.76) 0.60 (−0.06,1.27) 1.17 (0.51,1.84)
SDS (km/h) 2 2.00 2.06 2.11 2.18 0.07 (−0.05,0.18) 0.11 (−0.01,0.23) 0.18 (0.06,0.30)
9 1.90 1.98 2.00 2.06 0.08 (−0.04,0.20) 0.11 (−0.01,0.22) 0.16 (0.05,0.28)
Word learning test
Immediate recall (number correct) 2 43.7 45.4 45.3 43.6 1.7 (−0.9, 4.3) 1.6 (−1.0, 4.2) −0.0 (−2.7, 2.6)
9 45.5 45.7 46.6 44.9 0.2 (−2.4, 2.8) 1.1 (−1.5, 3.7) −0.6 (−3.2, 2.0)
Delayed recall (number correct) 2 8.6 8.8 8.6 7.8 0.3 (−0.7, 1.2) 0.0 (−0.9, 1.0) −0.8 (−1.7, 0.2)
9 8.9 9.2 8.8 8.0 0.3 (−0.7, 1.3) −0.0 (−1.0, 0.9) −0.8 (−1.8, 0.1)
Recognition (number correct) 2 26.8 27.3 27.2 26.8 0.5 (−0.4, 1.4) 0.3 (−0.5, 1.2) −0.1 (−1.0, 0.8)
9 26.9 27.1 26.6 25.8 0.3 (−0.6, 1.1) −0.3 (−1.2, 0.6) −1.0 (−1.9,−0.2)
Recognition speed (ms) 2 834 822 827 845 −12 (−47, 22) −8 (−43, 27) 11 (−24, 46)
9 821 831 805 847 10 (−25, 45) −16 (−51, 19) 26 (−9, 61)
Body Sway Test
A95 eyes opena (cm2) 2 1.15 1.18 1.28 1.25 1.03 (0.89, 1.18) 1.11 (0.97, 1.28) 1.08 (0.94, 1.25)
9 1.16 1.08 1.19 1.26 0.93 (0.81, 1.08) 1.03 (0.89, 1.18) 1.09 (0.94, 1.25)
A95 eyes closeda (cm2) 2 1.74 1.63 1.85 1.93 0.94 (0.83, 1.06) 1.07 (0.95, 1.20) 1.11 (0.98, 1.25)
9 1.76 1.73 1.52 1.89 0.98 (0.87, 1.11) 0.87 (0.77, 0.98) 1.08 (0.95, 1.21)
CoP eyes opena (cm) 2 50.7 52.0 51.5 50.0 1.03 (0.98, 1.07) 1.02 (0.98, 1.06) 0.99 (0.95, 1.03)
9 50.3 49.4 50.9 48.0 0.98 (0.94, 1.02) 1.01 (0.97, 1.05) 0.95 (0.92, 0.99)
CoP eyes closeda (cm) 2 66.4 66.8 67.1 63.7 1.01 (0.96, 1.06) 1.01 (0.96, 1.06) 0.96 (0.91, 1.01)
9 64.3 63.3 62.3 62.4 0.98 (0.94, 1.03) 0.97 (0.92, 1.02) 0.97 (0.92, 1.02)
Digit Symbol Substitution Test
DSST (number correct) 2 71.1 71.8 72.3 71.5 0.8 (−2.7, 4.2) 1.2 (−2.3, 4.6) 0.5 (−3.0, 3.9)
9 74.0 72.7 74.9 73.2 −1.3 (−4.8, 2.2) 0.9 (−2.6, 4.4) −0.8 (−4.3, 2.6)
Subjective rating scales
Instructor-rated Driving quality (mm) 2 33.4 35.9 37.2 38.0 2.5 (−1.7, 6.6) 3.8 (−0.4, 7.9) 4.6 (0.5, 8.8)
Very well (0)–Very bad (100) 9 35.3 35.5 33.7 38.9 0.2 (−3.9, 4.4) −1.5 (−5.7, 2.6) 3.6 (−0.5, 7.8)
Instructor-rated sedation (mm) 2 14.8 12.5 7.5 12.4 −2.3 (−6.8, 2.3) −7.3 (−11.8,−2.8) −2.4 (−6.9, 2.1)
None (0)–Completely (100) 9 6.9 8.1 9.8 9.5 1.3 (−3.3, 5.8) 3.0 (−1.6, 7.5) 2.6 (−1.9, 7.1)
Subject-rated alertness (mm) 2 17.2 17.3 17.2 16.9 0.1 (−0.9, 1.1) 0.0 (−1.0, 1.0) −0.3 (−1.2, 0.7)
Very alert (0)–Not alert (27) 9 15.8 15.6 16.1 15.3 −0.2 (−1.2, 0.8) 0.3 (−0.7, 1.3) −0.5 (−1.5, 0.5)
a Changes reflect fold-changes from placebo. Significant differences (values with CIs that do not overlap zero or 1 in the case of fold-change values) are
in italics. PBO, placebo; S15, suvorexant 15 mg; S30, suvorexant 30 mg; ZOP, zopiclone 7.5 mg
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words correctly recognized showed significant impairment in
ZOP on D9.
Body sway
No statistically significant impairment in body sway was ob-
served (Table 1).
DSST
No statistically significant impairment in DSST performance
was observed (Table 1).
Subjective evaluations
Subjects did not judge themselves significantly less alert in
any treatment condition as compared to placebo. Similarly, the
driving instructors did not judge the subjects as appearing
significantly more sedated in any treatment condition as
compared to placebo. Yet, they did rate the subjects driving
quality as significantly worse than placebo on D2 in ZOP
(Table 1).
Blood samples
On D2 mean (range) plasma concentrations of suvorexant
(C11h) were 0.259 (0.147 to 0.394) and 0.399 (0.217 to
0.687)μM, for 15 and 30mg doses, respectively. On D9mean
C11h increased to 0.394 (0.198 to 0.664) and 0.640 (0.312 to
1.241) μM, respectively. Mean (range) plasma concentrations
(C11h) of zopiclone were 19.19 (8.15 to 33.47) ng/ml on D2
and 17.97 (7.61 to 28.35) ng/ml on D9. There appeared to be
no clear relation between plasma concentrations of suvorexant
(pooled over dose) and SDLP, as shown by plots of individual
SDLP difference from placebo scores versus suvorexant plas-
ma concentration by gender (Supplementary Fig. S1).
Safety
Table 3 presents a summary of adverse events (AEs) reported by
≥5 % of the subjects after any treatment. After suvorexant, the
most common AEs were somnolence (8.3 % with S15; 29.2 %
with S30), headache (8.3 % with S15; 20.8 % with S30), and
poor sleep quality (25.0 % with S15; 0.0 % with S30).
After zopiclone, somnolence, headache, and dysgeusia
were the most common AEs (all 12.5 %). The remaining
AEs were reported by no more than two (8.3 %) subjects.
After placebo (which includes placebo treatment days 2 to
7 in ZOP), 13 subjects reported at least one adverse experi-
ence. All AEs were rated as mild or moderate in intensity.
Headache was the most frequently reported AE after placebo
(29.2 %), followed by somnolence (16.7 %), poor sleep qual-
ity (12.5 %), and nightmares (12.5 %). One female subject
was reported to have severe somnolence on D2 of PBOwhich
resulted in premature termination of the driving test.
No serious AEs and events of clinical interest, such as
cataplexy, were reported in this study, and there were no
Fig. 1 Individual SDLP (cm) differences from placebo (mean and 90 %
confidence interval) by treatment and day following bedtime
administration of suvorexant (MK-4305) 15 mg, 30 mg single dose
(day 2) and multiple doses (day 9), and single dose of zopiclone 7.5 mg
(day 2 and day 9), n = 24
Table 2 Symmetry analysis of
numbers of subjects whose SDLP
increased more than 2.4 cm
(indicating impairment) and
numbers of subjects whose SDLP
decreased more than 2.4 cm
(indicating improvement), n = 24
Treatment
condition
Day ΔSDLP ≥2.4 cm
n (proportion)
ΔSDLP ≤−2.4 cm
n (proportion)
Test
statistica
Reject
H0
S15 2 0 (0.00) 3 (0.13) −1.73 No
9 0 (0.00) 0 (0.00) ND No
S30 2 3 (0.13) 1 (0.04) 1 No
9 5 (0.21) 1 (0.04) 1.63 No
ZOP 2 8 (0.33) 0 (0.00) 2.83 Yes
9 6 (0.25) 1 (0.04) 1.89 Yes
a General sign test. Reject H0 (null hypothesis) if statistic >1.74 (indicates statistically significant imbalance). S15,
suvorexant 15 mg; S30, suvorexant 30 mg; ZOP, zopiclone 7.5 mg
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consistent treatment-related changes in laboratory, vital signs,
or ECG safety parameters.
Discussion
The primary aim of the current study was to assess the residual
effects of suvorexant 15 and 30 mg on car driving in older
adults, 9 h after single and repeated bedtime dosing. The pri-
marymeasure of driving performance was SDLP. Comparison
of mean drug-placebo changes and 90 % CIs to a pre-defined
criterion of 2.4 cm showed no clinically meaningful or statis-
tically significant effects of single and repeated doses of
suvorexant 15 and 30 mg on SDLP. All mean changes were
0.6 cm or less, and the 90 % CIs of these changes lay well
below the criterion of 2.4 cm and included zero. Symmetry
analyses of the numbers of subjects showing drug–placebo
changes in SDLP exceeding 2.4 or −2.4 cm showed a similar
lack of treatment effect. In line with this lack of effects on
SDLP, no significant effects of suvorexant on SD of speed
were observed.
Assay sensitivity was demonstrated by zopiclone 7.5 mg
on both days. Following this drug SDLP and SD speed sig-
nificantly increased as compared to placebo onD2 and D9. On
D2, the mean change in SDLP was +1.9 cm and 90 % CI
included 2.4 cm, indicating that impairment was also clinical-
ly meaningful. On D9, SDLP increased by 1.2 cm, and the
90 % CI lay above zero, but below 2.4 cm, indicating that the
effect was statistically significant (demonstrating assay sensi-
tivity), but not clinically meaningful.
Secondary and exploratory aims were to assess
suvorexant’s residual effects on memory, digit symbol substi-
tution, and postural balance. Results showed no significant
differences between suvorexant 15 and 30 mg and placebo
on performance in any of these tests. However, also no effects
of zopiclone were observed on immediate and delayed recall,
DSST and balance. Only word recognition was impaired by
zopiclone on D9.
Subjective ratings of driving quality were in line with the
performance effects as measured by SDLP. The driving in-
structors rated the subjects’ driving quality as significantly
worse than placebo only after the first dose of zopiclone.
After suvorexant and the second dose of zopiclone driving
quality was not judged to differ from placebo. Contrary to
ratings of driving quality, subjective ratings of sedation did
not discriminate between treatments.
In summary, there were no clinically meaningful or statis-
tically significant differences between effects of suvorexant 15
and 30 mg and placebo in a group of elderly volunteers, in
driving, cognitive and psychomotor performance, and subjec-
tive evaluations of performance and sedation. The lack of
residual effects in elderly subjects generally supports the con-
clusions of a previous study in non-elderly (21–65 years) vol-
unteers, also showing no clinically meaningful residual effects
of suvorexant (20 and 40 mg) with regard to mean changes in
SDLP (Vermeeren et al. 2015). However, the results of the
non-elderly study suggested that there may be some individ-
uals who experience next-day effects, as suggested by indi-
vidual changes in SDLP and prematurely stopped tests. In the
present study, after the 15 mg dose, which is in the FDA-
approved dose range, none of the elderly subjects showed
driving impairment on either day 2 or day 9. On the contrary,
three subjects driving seemed to improve after this dose on D2
(see Fig. 1).
The mean change in SDLP after the first dose of zopiclone
on SDLP was +1.9 cm, and the associated 90 % CI included
the criterion of 2.4 cm. This shows that the zopiclone effect
was comparable to that of driving under the influence of alco-
hol with a blood alcohol concentration of 0.5 g/L, which is the
legal limit for driving in most countries. The effect of
zopiclone on D2 in the present study is comparable to that
found previously in healthy older drivers (Leufkens and
Vermeeren 2009). The effect was smaller on D9 (+1.2 cm).
A similar decrease in the effect of zopiclone from D2 to D9
with repeat of single doses was found in a previous study with
suvorexant in non-elderly subjects (Vermeeren et al. 2015).
Although the difference in effects on D2 and D9 is small, it
Table 3 Summary of AEs
reported by at least 5 % of the
subjects after any treatment,
n = 24
PBOa n (%) S15 n (%) S30 n (%) ZOP n (%)
Subjects with at least 1 AE 13 (54.2) 14 (58.3) 13 (54.2) 11 (45.8)
Headache 7 (29.2) 2 (8.3) 5 (20.8) 3 (12.5)
Somnolence 4 (16.7) 2 (8.3) 7 (29.2) 3 (12.5)
Dysgeusia 0 (0.0) 0 (0.0) 0 (0.0) 3 (12.5)
Fatigue 0 (0.0) 2 (8.3) 1 (4.2) 1 (4.2)
Dizziness 0 (0.0) 0 (0.0) 0 (0.0) 2 (8.3)
Poor sleep quality 3 (12.5) 6 (25.0) 0 (0.0) 0 (0.0)
Nightmare 3 (12.5) 1 (4.2) 2 (8.3) 1 (4.2)
a Includes placebo treatment days 2 to 7 in ZOP. PBO, placebo; S15, suvorexant 15 mg; S30, suvorexant 30 mg;
ZOP, zopiclone 7.5 mg
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does raise the question of what may have caused it. Since
zopiclone was administered as single doses, these findings
cannot easily be explained by development of physiological
tolerance. Plasma concentrations of zopiclone were compara-
ble on both days. Practice effects are also not likely. Driving
performance after placebo does not consistently improve with
repeated testing. Out of 14 studies repeatedly assessing the
driving performance after placebo, six showed a decrease in
mean SDLP with repeated testing, whereas eight studies
showed an increase in mean SDLP (Vermeeren and O’Hanlon
1998; Vermeeren et al. 2002, 2015; Ramaekers et al. 1994,
1995, 2006, 2011; Brookhuis et al. 1993; Conen et al. 2011;
O’Hanlon et al. 1998; Robbe and O’Hanlon 1995; Theunissen
et al. 2006; Verster et al. 2003; Wingen et al. 2005). In the
present study, SDLP decreased slightly from day 2 to day 9
after placebo. This improvement is smaller however, than the
reduction in effect of zopiclone. As suggested for the previous
study (Vermeeren et al. 2015), the reduced effect of zopiclone
could be due to the development of behavioral tolerance after
single exposure to its effects, i.e., development of behavioral
strategies to compensate for the drug’s effects on driving per-
formance, as seen with alcohol (Vogel-Sprott 1997).
The lack of residual effects of zopiclone in word learning,
DSST, and body sway is in contrast with results of previous
studies showing significant residual impairment after
zopiclone in these tests (Vermeeren et al. 1998, 2002, 2015;
Leufkens and Vermeeren 2009; Leufkens et al. 2009; Mets
et al. 2011). The discrepancy may be due to age-related dif-
ferences in placebo performance between studies. Subjects in
the present study were older than in previous studies, and their
performance in these tests was relatively worse. It may be that
their placebo performance in these tests did not allow much
further impairment due to zopiclone (i.e., floor effects).
On average subjects’ SDLP scores in the placebo condition
were comparable to that in studies with younger volunteers
(Vermeeren et al. 2014, 2015; Jongen et al. 2015). Only one
driving test, for a 72-year-old female subject, was terminated
prematurely by the driving instructor after 45 min on D2 in
period 4, while on placebo treatment. The driving instructor
judged the subject too drowsy to continue safely. No driving
tests were stopped after subjects received suvorexant or
zopiclone in this study. Termination of driving tests after place-
bo has occurred before, although the prevalence is low. A re-
view of 47 published papers on double-blind, placebo-
controlled studies using the highway driving test to assess drug
effects on driving, found that 0.7% of the driving tests had been
terminated before completion after placebo treatment, whereas
4.1 % were stopped after drug treatment. The results confirmed
the conclusion that the decision to stop a driving test is not a
reliable correlate of objective driving performance (O’Hanlon
1984; Verster and Roth 2012).
Plasma concentrations of suvorexant were in the expected
dose-range, and in line with those found in the previous study
assessing effects of suvorexant 20 and 40 mg on driving in
non-elderly subjects. Plasma concentrations of zopiclone in
this sample of elderly (19.2 and 18.0 ng/ml) were on average
slightly increased compared to those previously found in non-
elderly (15.6 and 15.8 ng/ml).
The use of healthy volunteers instead of patients could be
considered a limitation of this study. An important reason to
study the effects of suvorexant in healthy volunteers is to facil-
itate comparisons to previous driving studies, which were vir-
tually all conducted with normal volunteers (Vermeeren 2004,
Vermeeren et al. 2014; Leufkens et al. 2009, 2014; Mets et al.
2011; Ramaekers et al. 2011). More importantly, a recent study
comparing the effects of zopiclone on driving in middle-aged
patients with insomnia andmiddle-aged healthy volunteers sug-
gests that healthy volunteers may be more sensitive to the re-
sidual effects (Leufkens et al. 2014). Thus, studying drug ef-
fects in healthy volunteers minimizes the risk of failing to detect
clinically relevant impairment associated with use of a drug.
In conclusion, results of the present study show that single
and repeated doses of suvorexant 15 and 30 mg are not asso-
ciated with next-day residual impairment in elderly subjects as
assessed by on-the-road driving performance, balance, and
cognitive tests. Due to individual variation, patients taking
suvorexant should be advised not to drive, operate machinery,
or engage in other activities requiring full mental alertness
until fully awake.
Acknowledgments The authors thank Henk Brauers, Jo Gorissen,
Hans Sleebe, Bert Adriaens, and Eef Gorissen from Maastricht
University for ensuring safety of the subjects during driving, and
Christopher Lines from Merck for assistance in editing the manuscript.
Funding This study was financially supported by Merck & Co. Inc.,
Kenilworth, NJ, USA. Maastricht University and SGS Life Sciences re-
ceived financial support from Merck & Co. Inc. to conduct this study.
Merck&Co. Inc. is themanufacturer of suvorexant under the brand name
Belsomra®.
Conflict of interest Drs. Vermeeren, Vuurman, Jongen, and Ms. Van
Oers are employees of Maastricht University. Dr. Vets is employee of
SGS Life Science Services. The remaining authors are current or former
employees ofMerck Sharp & Dohme Corp., a subsidiary ofMerck & Co.
Inc. Kenilworth NJ, USA, and own or owned stock/stock options in
Merck. Dr. Sun is currently affiliated with Amgen in ThousandOaks, CA.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
Bain KT (2006)Management of chronic insomnia in elderly persons. Am
J Geriatr Pharmacother 4:168–192
Psychopharmacology (2016) 233:3341–3351 3349
Bond A, Lader M (1974) The use of analogue scales in rating subjective
feelings. Br J Med Psychol 47:211–218
Boyle J, Danjou P, Alexander R, et al. (2009) Tolerability, pharmacoki-
netics and night-time effects on postural sway and critical flicker
fusion of gaboxadol and zolpidem in elderly subjects. Br J Clin
Pharmacol 67:180–190
Brookhuis KA, De Vries G, De Waard D (1993) Acute and subchronic
effects of the H1-histamine receptor antagonist ebastine in 10, 20
and 30 mg dose, and triprolidine 10 mg on car driving performance.
Br J Clin Pharmacol 36:67–70
Conen S, Theunissen EL, Van Oers AC, Valiente R, Ramaekers JG
(2011) Acute and subchronic effects of bilastine (20 and 40 mg)
and hydroxyzine (50 mg) on actual driving performance in healthy
volunteers. J Psychopharmacol 25:1517–1523
Cox CD, Breslin MJ, Whitman DB, et al. (2010) Discovery of the dual
orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-
7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-
yl)phenyl]methanone (MK-4305) for the treatment of insomnia. J
Med Chem 53:5320–5332
Dassanayake T, Michie P, Carter G, Jones A (2011) Effects of benzodi-
azepines, antidepressants and opioids on driving: a systematic re-
view and meta-analysis of epidemiological and experimental evi-
dence. Drug Saf 34:125–156
De Lecea L, Huerta R (2014) Hypocretin (orexin) regulation of sleep-to-
wake transitions. Front Pharmacol 5:16
Drake CL, Roehrs T, Roth T (2003) Insomnia causes, consequences, and
therapeutics: an overview. Depress Anxiety 18:163–176
Food and Drug Administration (2015) Evaluating drug effects on the
ability to operate a motor vehicle. Guidance for industry. January
2015. Available at: http://www.fda.gov/downloads/Drugs//
G u i d a n c e C om p l i a n c e R e g u l a t o r y I n f o r m a t i o n /
Guidances/UCM430374.pdf
Fulcher BD, Phillips AJ, Postnova S, Robinson PA (2014) A physiolog-
ically based model of orexinergic stabilization of sleep and wake.
PLoS One 9:e91982
Glass J, Lanctot KL, Herrmann N, Sproule BA, Busto UE (2005)
Sedative hypnotics in older people with insomnia: meta-analysis
of risks and benefits. BMJ 331:1169–1175
Herring WJ, Snyder E, Budd K, et al. (2012) Orexin receptor antagonism
for treatment of insomnia: a randomized clinical trial of suvorexant.
Neurology 79:2265–2274
Herring WJ, Connor KM, Ivgy-May N, et al. (2016) Suvorexant in pa-
tients with insomnia: results from two 3-month randomized con-
trolled clinical trials. Biol Psychiatry 79:136–148. doi:10.1016/j.
biopsych.2014.10.003.
Jongen S, Vuurman EF, Ramaekers JG, Vermeeren A (2014) Alcohol
calibration of tests measuring skills related to car driving.
Psychopharmacology 231:2435–2447
Jongen S, Perrier J, Vuurman EF, Ramaekers JG, Vermeeren A (2015)
Sensitivity and validity of psychometric tests for assessing driving
impairment: effects of sleep deprivation. PLoS One 10:e0117045.
doi:10.1371/journal.pone.0117045
Leufkens TR, Vermeeren A (2009) Highway driving in the elderly the
morning after bedtime use of hypnotics: a comparison between
temazepam 20 mg, zopiclone 7.5 mg, and placebo. J Clin
Psychopharmacol 29:432–438
Leufkens TR, Vermeeren A (2014) Zopiclone’s residual effects on actual
driving performance in a standardized test: a pooled analysis of age
and sex effects in 4 placebo-controlled studies. Clin Ther 36:141–
150
Leufkens TR, Lund JS, Vermeeren A (2009) Highway driving perfor-
mance and cognitive functioning the morning after bedtime and
middle-of-the-night use of gaboxadol, zopiclone and zolpidem. J
Sleep Res 18:387–396
Leufkens TR, Ramaekers JG, de Weerd AW, Riedel WJ, Vermeeren A
(2014) Residual effects of zopiclone 7.5 mg on highway driving
performance in insomnia patients and healthy controls: a placebo
controlled crossover study. Psychopharmacology 231:2785–2798
Louwerens JW, Gloerich ABM,DeVries G, Brookhuis KA, O’Hanlon JF
(1987) The relationship between drivers’ blood alcohol concentra-
tion (BAC) and actual driving performance during high speed travel.
In: International Congress on Alcohol, Drugs and Traffic Safety,
183–6. Amsterdam, Exerpta Medica
Merck & Co. Inc. (2014) BELSOMRA ® (suvorexant) prescribing infor-
mation. Merck & Co., Inc., Whitehouse Station
Mets MA, de Vries JM, Senerpont Domis LM, Volkerts ER, Olivier B,
Verster JC (2011) Next-day effects of ramelteon (8 mg), zopiclone
(7.5 mg), and placebo on highway driving performance, memory
functioning, psychomotor performance, and mood in healthy adult
subjects. Sleep 34:1327–1334
Michelson D, Snyder E, Paradis E, et al. (2014) Safety and efficacy of
suvorexant during 1-year treatment of insomnia with subsequent
abrupt treatment discontinuation: a phase 3 randomised, double-
blind, placebo-controlled trial. Lancet Neurol 13:461–471
Norris JA, Marsh AP, Smith IJ, Kohut RI, Miller ME (2005) Ability of
static and statistical mechanics posturographic measures to distin-
guish between age and fall risk. J Biomech 38:1263–1272
O’Hanlon JF (1984) Driving performance under the influence of drugs:
rationale for, and application of, a new test. Br J Clin Pharmacol
18(Suppl 1):121S–129S
O’Hanlon JF, Robbe HW, Vermeeren A, van Leeuwen C, Danjou PE
(1998) Venlafaxine’s effects on healthy volunteers’ driving, psycho-
motor, and vigilance performance during 15-day fixed and incre-
mental dosing regimens. J Clin Psychopharmacol 18:212–221
Otmani S, Metzger D, Guichard N, Danjou P, Nir T, Zisapel N, Katz A
(2012) Effects of prolonged-release melatonin and zolpidem on pos-
tural stability in older adults. Hum Psychopharmacol 27:270–276
Ramaekers JG, van Veggel LM, O’Hanlon JF (1994) A cross-study com-
parison of the effects of moclobemide and brofaromine on actual
driving performance and estimated sleep. Clin Neuropharmacol
17(Suppl 1):S9–18
Ramaekers JG, Muntjewerff ND, O’Hanlon JF (1995) A comparative
study of acute and subchronic effects of dothiepin, fluoxetine and
placebo on psychomotor and actual driving performance. Br J Clin
Pharmacol 39:397–404
Ramaekers JG, Louwerens JW, Muntjewerff ND, et al. (1999)
Psychomotor, cognitive, extrapyramidal, and affective functions of
healthy volunteers during treatment with an atypical (amisulpride)
and a classic (haloperidol) antipsychotic. J Clin Psychopharmacol
19:209–221
Ramaekers JG, Kuypers KP, Samyn N (2006) Stimulant effects of 3,4-
methylenedioxymethamphetamine (MDMA) 75 mg and methyl-
phenidate 20 mg on actual driving during intoxication and with-
drawal. Addiction 101:1614–1621
Ramaekers JG, Conen S, de Kam PJ, et al. (2011) Residual effects of
esmirtazapine on actual driving performance: overall findings and
an exploratory analysis into the role of CYP2D6 phenotype.
Psychopharmacology 215:321–332
Robbe HW, O’Hanlon JF (1995) Acute and subchronic effects of parox-
etine 20 and 40mg on actual driving, psychomotor performance and
sub j ec t i ve as s e s smen t s in hea l t hy vo lun t ee r s . Eu r
Neuropsychopharmacol 5:35–42
Smink BE, Egberts AC, Lusthof KJ, Uges DR, De Gier JJ (2010) The
relationship between benzodiazepine use and traffic accidents: a
systematic literature review. CNS Drugs 24:639–653
Sun H, Kennedy WP, Wilbraham D, et al. (2013) Effects of suvorexant,
an orexin receptor antagonist, on sleep parameters as measured by
polysomnography in healthy men. Sleep 36:259–267
Theunissen EL, Vermeeren A, Ramaekers JG (2006) Repeated dose ef-
fects of mequitazine, cetirizine and dexchlorpheniramine on driving
and psychomotor performance. Br J Clin Pharmacol 61:79–86
3350 Psychopharmacology (2016) 233:3341–3351
Vermeeren A (2004) Residual effects of hypnotics: epidemiology and
clinical implications. CNS Drugs 18:297–328
VermeerenA, O’Hanlon JF (1998) Fexofenadine’s effects, alone and with
alcohol, on actual driving and psychomotor performance. J Allergy
Clin Immunol 101:306–311
Vermeeren A, Danjou PE, O’Hanlon JF (1998) Effects of evening and
middle of the night doses of zaleplon 10 and 20 mg on memory
and actual driving performance. Hum Psychopharmacol 13:S98–
S107
Vermeeren A, Riedel WJ, van Boxtel MP, Darwish M, Paty I, Patat A
(2002) Differential residual effects of zaleplon and zopiclone on
actual driving: a comparison with a low dose of alcohol. Sleep 25:
224–231
VermeerenA,Vuurman EF, Leufkens TR, et al. (2014) Residual effects of
low-dose sublingual zolpidem on highway driving performance the
morning after middle-of-the-night use. Sleep 37:489–496
Vermeeren A, Sun H, Vuurman E, et al. (2015) On-the-road driving
performance the morning after bedtime use of suvorexant 20 and
40 mg: a study in non-elderly healthy volunteers. Sleep 38:1803–
1813
Verster JC, Roth T (2012) The prevalence and nature of stopped on-the-
road driving tests and the relationship with objective performance
impairment. Accid Anal Prev 45:498–506
Verster JC, Volkerts ER, van Oosterwijck AW, et al. (2003) Acute and
subchronic effects of levocetirizine and diphenhydramine on mem-
ory functioning, psychomotor performance, and mood. J Allergy
Clin Immunol 111:623–627
Vogel-Sprott M (1997) Is behavioral tolerance learned? Alcohol Health
Res World 21:161–168
Wingen M, Bothmer J, Langer S, Ramaekers JG (2005) Actual driving
performance and psychomotor function in healthy subjects after
acute and subchronic treatment with escitalopram, mirtazapine,
and placebo: a crossover trial. J Clin Psychiatry 66:436–443
Woodward M (1999) Hypnosedatives in the elderly. CNS Drugs 11:263–
279
Psychopharmacology (2016) 233:3341–3351 3351
